Anteris Provides Update on DurAVR™ THV Valve-in-Valve Experience Presented at New York Valves 2024
DurAVR ViV restores similar aortic valve gradients to initial post-surgical results
Dr
Unique Challenges of ViV Procedures
While TAVR procedures have revolutionized heart valve replacement, up to 30% of patients may eventually require a second valve due to deterioration of the first implant1. Transcatheter ViV replacement is performed by implanting a transcatheter heart valve within a failing bioprosthetic aortic valve. The transcatheter ViV operation is a less invasive procedure compared with reoperative surgical aortic valve replacement however this repeat procedure presents unique challenges for both doctors and patients.
"Valve-in-valve procedures often force us to make difficult choices," explained
Restoring Valve Hemodynamics with DurAVR™
ViV implantation with DurAVR™ THV successfully reduced aortic valve gradients to a level similar to the initial post-surgical valve gradient.
Average aortic valve gradients across the series of 5 cases:
- Post-surgical valve replacement gradient (8-13 years prior) = 13.82 mmHg
- Mean gradient prior to ViV = 58.60 mmHg
- 30 day core lab echo data post DurAVR™ ViV = 13.76 mmHg
No major complications were reported.
About
The Company’s lead product, DurAVRTM, is a transcatheter heart valve (THV) for treating aortic stenosis. DurAVRTM THV was designed in partnership with the world’s leading interventional cardiologists and cardiac surgeons. It is the first transcatheter aortic valve replacement (TAVR) to use a single piece of bioengineered tissue. This biomimetic valve is uniquely shaped to mimic the performance of a healthy human aortic valve.
DurAVRTM THV is made using ADAPT® tissue, Anteris’ patented anti-calcification tissue technology. ADAPT® tissue has been used clinically for over 10 years and distributed for use in over 55,000 patients worldwide.
The ComASURTM Delivery System was designed to provide controlled deployment and accurate placement of the DurAVRTM THV with balloon-expandable delivery, allowing precise alignment with the heart’s native commissures to achieve optimal valve positioning.
Authorisation and Additional information
This announcement was authorised by Mr.
Website |
||
|
||
|
||
|
- Giordana, F., Bruno, F., Controtto, F. et al. Incidence, predictors and outcomes of valve-in-valve TAVI: A systematic review and meta-analysis. Int. J. Cardiol.316 (2020). https://doi.org/10.1016/j.ijcard.2020.05.058
View source version on businesswire.com: https://www.businesswire.com/news/home/20240613860232/en/
Investor Relations
investors@anteristech.com
+61 1300 550 310 | +61 7 3152 3200
Investor
Relations (US)
Managing Director
+1 917 330 4269
Source: